For Immediate Release
January 12, 2026
Cranford, NJ– WBB Securities, LLC has initiated research coverage of Turn Therapeutics, Inc. (NasdaqCM: TTRX), a clinical-stage biotechnology company focused on developing therapies for inflammatory skin and infectious diseases.
The report highlights Turn Therapeutics’ proprietary PermaFusion® delivery platform, its advancing dermatology pipeline, and upcoming clinical milestones expected in 2026.
The initiation report was authored by Karen Sterling, PhD, CFA, Research Analyst at WBB Securities. Dr. Sterling brings deep experience in life sciences research and valuation, and her analysis outlines the clinical progress and long-term potential of Turn’s platform-based approach.
The full research report is available here.
About WBB Securities.
WBB Securities is a leading Investment Management, Investment Banking, and Equity Research firm focused primarily in the life sciences niche. Established in 2001 with offices in New Jersey, New York, and California. WBB Securities is registered with the SEC as a broker-dealer, a member of FINRA, and a state-registered investment advisor with a proprietary trading desk. The firm is comprised of a nationwide team of respected senior investment and research professionals serving institutional and high-net-worth clients.
About Turn Therapeutics.
Turn Therapeutics is a biotechnology company developing and commercializing products for dermatology, wound care, and infectious disease. The Company has received three FDA clearances for its proprietary wound and dermatology formulations and is advancing late-stage clinical programs in eczema and onychomycosis. In addition, Turn is pursuing global health initiatives in thermostable vaccine delivery designed to serve underserved areas worldwide, reflecting its commitment to public health innovation.
